Blood tests could Fine-Tune kidney cancer treatment
NCT ID NCT02555748
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether measuring drug levels in the blood can help doctors adjust doses of two common kidney cancer medications, sunitinib and pazopanib. The goal was to see if this personalized approach reduces side effects and keeps the cancer from growing longer than the standard method of dosing based on side effects alone. The study enrolled 47 patients with advanced or metastatic renal cell carcinoma starting these drugs as their first treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib and pazopanib
What this could lead to
If successful, this approach could help doctors personalize dosing of these drugs to reduce side effects and improve treatment effectiveness for kidney cancer patients.
What could go wrong
This is a small pilot study with only 47 participants, so results may not apply to everyone. The approach adds complexity and may not significantly improve outcomes over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH RODEZ
Rodez, 12027, France
-
CHU DE BORDEAUX - Hôpital Saint-André
Bordeaux, 33035, France
-
CHU DE LIMOGES - Hôpital Dupuytren
Limoges, 87042, France
-
Centre Leon Berard
Lyon, 69373, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut Regional Du Cancer Montpellier
Montpellier, 34298, France